Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Douglas Middleton Dahl, M.D.

Co-Author

This page shows the publications co-authored by Douglas Dahl and Jason Efstathiou.
Connection Strength

0.741
  1. Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer. J Urol. 2018 02; 199(2):407-415.
    View in: PubMed
    Score: 0.181
  2. Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience. Clin Genitourin Cancer. 2017 Aug 03.
    View in: PubMed
    Score: 0.180
  3. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017 06; 71(6):952-960.
    View in: PubMed
    Score: 0.173
  4. Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy. J Urol. 2021 Jul; 206(1):29-36.
    View in: PubMed
    Score: 0.058
  5. Reply by Authors. J Urol. 2019 10; 202(4):821-822.
    View in: PubMed
    Score: 0.052
  6. Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. J Urol. 2019 04; 201(4):721-727.
    View in: PubMed
    Score: 0.051
  7. An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. Cancer Discov. 2018 03; 8(3):288-303.
    View in: PubMed
    Score: 0.046
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.